STAT

‘On a knife edge’: Ebola outbreak threatens to escalate as violence rises

As violence aimed at response workers increases, the #Ebola outbreak in the Congo threatens to spiral out of control.
Doctors and health workers marched in the Eastern Congo town of Butembo in April, after attackers shot and killed an epidemiologist from Cameroon who was working for the WHO.

The Ebola outbreak in the Democratic Republic of the Congo is threatening to spiral out of control, with ongoing violence aimed at the Ebola response workers undermining efforts to stop spread of the deadly virus.

STAT spoke to a number of experts involved with or closely monitoring the situation to try to get a sense of where the outbreak in northeastern DCR is heading.

Each one agreed: A disaster is unfolding.

“The numbers in the last month have been horrifying,” said Dr. Jeremy Farrar, director of the Wellcome Trust, a major funder of the Ebola response. “It’s on a knife edge. I’m not sure how else to describe it, really.”

The World Health Organization is doing scenario mapping trying to figure out just how bad this outbreak might become. But Dr. Mike Ryan, executive director of the emergencies program, won’t share what they see as they look at their models. “That’s for planning purposes, not for speculation,” Ryan insisted in an interview with STAT on Monday.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks